| Theme | Antiplatelet and Anticoagulation Therapy in Patients with Chronic Kidney Disease -- up to date of evidence | |
|---|---|---|
| Title | Anticoagulation and antiplatelet therapy for CKD patients | |
| Publish Date | 2012/07 | |
| Author | Yoshiyuki Miyahara | Nagasaki Memorial Hospital |
| Author | Satoshi Ikeda | Cardiovascular Medicine, Nagasaki University Hospital |
| [ Summary ] | PTE and DVT are forms of pathophysiology generically termed VTE. Acute PTE is caused by abrupt blockage of pulmonary vessels by thrombi which have formed in deep veins and traveled through the bloodstream. Basic components of VTE treatment are anticoagulation therapy, using unfracionated heparin in the initial phase (five-seven days) and warfarin in the following stage. Warfarin is also used to treat CKD patients. Heparin should be used to treat these patients unless it is absolutely contraindicated. Treatment must be initiated before confirming the diagnosis. The major complication associated with anticoagulation thrapy is bleeding. CKD patients, especially hemodialysis patients, are susceptible to bleeding. Anticoagulation therapy should be performed with great care. |
|